Trial · NCT07905950
Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer
NCT07905950, Phase 2, Not yet recruiting, Henan Cancer Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer. Trials, record NCT07905950. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905950
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer
- NCT number
- NCT07905950
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 155 participants, estimated
- Lead sponsor
- Henan Cancer Hospital
- Conditions
- Locally Advanced Resectable Rectal Cancer
- Interventions
- Adebrelimab
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | the complete response (CR) rate assessed at the end of Cycle 4 or Cycle 8 | at the end of Cycle 4 or Cycle 8(each cycle is 21 days). | |
| Secondary | The 3-year event-free survival (EFS) rate | At 36 months after treatment initiation. | |
| Secondary | 3-year overall survival (OS) rate | At 36 months after treatment initiation. | |
| Secondary | The median event-free survival (mEFS) | From date of treatment initiation until the first documented disease progression, recurrence, or death from any cause, whichever occurs first, up to 60 months. | |
| Secondary | The median overall survival (mOS) | From date of treatment initiation until death from any cause, , up to 60 months. | |
| Secondary | The local recurrence rate (LRR) | Within 3 years after treatment initiation. | |
| Secondary | R0 resection rate | At the time of surgery. | |
| Secondary | distant metastasis rate (DM) | Within 3 years after treatment initiation. | |
| Secondary | The organ preservation rate | Within 3 years after treatment initiation. | |
| Secondary | incidence of adverse events (AEs) | From date of treatment initiation until 30 days after the last dose of study treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905950
GET https://conductscience.org/api/trials/v1/NCT07905950/registered